BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC). but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targ... https://parisnaturalfoodes.shop/product-category/gum-wintergreen/
Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
Internet - 2 minutes ago pdobabh0snsjWeb Directory Categories
Web Directory Search
New Site Listings